Biotechnology research company Qvin™ has achieved FDA clearance for its Q-Pad™ and A1c Test, marking a significant breakthrough in women’s diabetic patients. Qvin’s innovative approach involves collecting menstrual blood samples as an alternative to traditional venous blood draws, providing a convenient and accessible method for monitoring A1c levels, particularly beneficial for the millions of women in the U.S. living with diabetes.

Menstrual blood, previously unexplored as a diagnostic source, proves clinically relevant for essential biomarkers. Traditionally, blood testing involves invasive and time-consuming procedures, often requiring professional administration. Qvin’s Q-Pad technology, simplifies routine testing, freeing up resources, and making healthcare more accessible. Now FDA-cleared for at-home sample collection and over-the-counter distribution, revolutionizes routine testing.

The Q-Pad includes a removable strip, with collected menstrual samples sent to a CLIA-Certified laboratory for testing, and results conveniently delivered through the Qvin app. The A1c Q-Pad Test Kit measures three-month average blood sugar levels, vital for diabetes monitoring. Beyond diabetes, Qvin’s technology addresses critical women’s health issues historically neglected, including pre/diabetes, anemia, fertility, perimenopause, endometriosis, and thyroid health.

Søren Therkelsen, Qvin Co-founder, emphasizes the potential for Qvin’s vertically integrated infrastructure to deliver healthcare solutions at a lower cost than traditional methods. Collaborating with institutions like Stanford University School of Medicine, Qvin’s peer-reviewed research validates monitoring various reproductive hormones via menstrual blood for fertility assessment.

The Q-Pad also presents a user-friendly method for screening the Human Papilloma Virus (HPV) as part of global cervical cancer prevention efforts.

Article written by QVIN